Telomir Pharmaceuticals (TELO) Retained Earnings (2022 - 2026)
Telomir Pharmaceuticals (TELO) posted Retained Earnings of -$41.0 million for Q4 2025, down 189.29% sequentially from $45.9 million in Q3 2025, and down 34.03% YoY from -$62.2 million in Q4 2024.
Telomir Pharmaceuticals (TELO) Retained Earnings (2022 - 2026) Analysis & Trends
Telomir Pharmaceuticals has reported Retained Earnings for 4 years, with the latest figure at -$41.0 million in Q4 2025.
- Quarterly Retained Earnings fell 34.03% year-over-year to -$41.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$41.0 million (down 34.03% YoY) and the FY2025 annual result came in at -$41.0 million, down 34.03% from the prior year.
- Retained Earnings retreated to -$41.0 million in Q4 2025 per TELO's latest filing, from $45.9 million in the prior quarter.
- Over five years, Retained Earnings peaked at $45.9 million in Q3 2025 and troughed at -$41.0 million in Q4 2025.
- A 4-year average of $4.9 million and a median of $11.2 million in 2022 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2025: Retained Earnings tumbled 1317.36% in 2023, then jumped 265.81% in 2025.
- Over 4 years, Retained Earnings stood at -$992278.0 in 2022, then sank by 1317.36% to -$14.1 million in 2023, then plunged by 117.55% to -$30.6 million in 2024, then sank by 34.03% to -$41.0 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered -$41.0 million, $45.9 million, and $38.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -6.33 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.57 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 4.38 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 20.91 Bn |
| 10 | Telomir Pharmaceuticals | 68.14 Mn | 68.14 Mn | - | 48.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.76 Mn |
| Dec 31, 2025 | -41.01 Mn |
| Sep 30, 2025 | 45.93 Mn |
| Jun 30, 2025 | 38.33 Mn |
| Mar 31, 2025 | 32.62 Mn |
| Dec 31, 2024 | -30.60 Mn |
| Sep 30, 2024 | -27.70 Mn |
| Jun 30, 2024 | 23.34 Mn |
| Mar 31, 2024 | 23.34 Mn |
| Dec 31, 2023 | -14.06 Mn |
| Dec 31, 2022 | -992,278.00 |